S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Closing prices for crude oil, gold and other commodities
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
LON:IXI

IXICO (IXI) Share Price, News & Analysis

GBX 8.75
0.00 (0.00%)
(As of 04/19/2024 ET)
Today's Range
8.35
8.75
50-Day Range
7.19
10.50
52-Week Range
6.35
21
Volume
52,401 shs
Average Volume
91,915 shs
Market Capitalization
£4.23 million
P/E Ratio
N/A
Dividend Yield
1.27%
Price Target
N/A
IXI stock logo

About IXICO Stock (LON:IXI)

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, an online digital platform for clinics; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. In addition, the company focuses in therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis, and orphan and rare diseases. Further, the company engages in the data collection and analysis of neurological disorders. Additionally, it offers drug development analytics, imaging operation, post marketing surveillance, and consultancy services; and end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

IXI Stock Price History

IXI Stock News Headlines

Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Is IXICO plc (LON:IXI) Potentially Undervalued?
IXICO plc (PYPB.F)
IXICO 'on track' to achieve full-year guidance
IXICO upbeat on prospects as it eyes double-digit growth
See More Headlines
Receive IXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IXICO and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/20/2020
Today
4/20/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
89
Year Founded
N/A

Profitability

Net Income
£-1,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£6.67 million
Cash Flow
GBX 3.89 per share
Book Value
GBX 24 per share

Miscellaneous

Free Float
N/A
Market Cap
£4.23 million
Optionable
Not Optionable
Beta
0.67
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Giulio Cerroni (Age 63)
    CEO & Director
    Comp: $328k
  • Mr. Grant Nash
    CFO, Company Secretary & Executive Director
  • Prof. Daniel Rueckert
    Co-Founder & Member of Scientific Advisory Board
  • Prof. Derek Lionel Glendon Hill (Age 58)
    Co-Founder and President of Regulatory Science & External Relations
    Comp: $387.01k
  • Prof. David Hawkes CPhys
    FInstP, FIPEM, FREng, Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Prof. Joseph Hajnal
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Romina Oxborough Ph.D.
    Senior Vice President of Operations
  • Mr. Mark Austin
    Director of Technology
  • Dr. Robin Wolz
    Chief Scientific Officer
  • Ms. Hannah Esfahanian
    HR Manager

IXI Stock Analysis - Frequently Asked Questions

How have IXI shares performed in 2024?

IXICO's stock was trading at GBX 12.50 at the beginning of 2024. Since then, IXI shares have decreased by 30.0% and is now trading at GBX 8.75.
View the best growth stocks for 2024 here
.

How were IXICO's earnings last quarter?

IXICO plc (LON:IXI) released its earnings results on Wednesday, May, 20th. The company reported $1.01 earnings per share (EPS) for the quarter. IXICO had a negative net margin of 17.67% and a negative trailing twelve-month return on equity of 9.85%.

What other stocks do shareholders of IXICO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IXICO investors own include Motif Bio (MTFB), ReNeuron Group (RENE), Pendragon (PDG), EnQuest (ENQ) and Chariot (CHAR).

How do I buy shares of IXICO?

Shares of IXI stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:IXI) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners